Jump to content

Why has trade on the Clover Health share price been so volatile?


MongiIG

Recommended Posts

The Clover Health share price is down 50% year to date as the company finds itself under a SEC investigation and loses SPAC appeal.

TradersSource: Bloomberg
 

 

 Shaun Murison | Senior Market Analyst, Johannesburg | Publication date: Thursday 22 July 2021 

Who is Clover Health Investments Corporation?

Clover Health Investments Corp, is a healthcare technology company providing medicare advantage (MA) insurance plans to seniors. The groups offering includes hospital coverage, doctor visits, drug coverage, vision, dental, and hearing coverage.

The group also offers a software platform called the Clover Assistant, provide American seniors with highly affordable, 'obvious' healthcare plans. The company’s flagship software provides physicians with data-driven, personalised insights at the point of care.

Is Clover Health a SPAC?

Clover’s listed debut was through a merger with special purpose acquisition company (SPAC) Social Capital Hedosophia Holdings Corp III late in 2020

Why has the Clover Health share price under pressure?

A share price surge in the middle of the year (2021) appears to have dovetailed with moves in so called ‘meme’ and ‘SPAC’ stocks. The unprecedented gains can largely be attributed to speculative investments from retail traders coordinated on forums such as Reddit (WallStreetBets). These short term gains were however quickly unwound.

The Clover Health share price is down more than 50% year to date (as of 21 July 2021). The company boasts exciting propositions to help better a widely criticised US healthcare system, although the group remains unprofitable at present.

While the company originally forecast ambitious membership numbers in 2021, these numbers have been revised lower as the year has progressed. Clover Health is now also under investigation by the US Securities and Exchange Commission (SEC) on allegations that the company and its promoter, Chamath Palihapitiya, misled investors while promoting the business.

Clover Health share price – technical analysis

 

Clover Health chartSource: IG charts

 

The share price of Clover Health has been in a sharp downtrend since June this year. The aggressive decline now sees its historical low at 6.20 as the next support target from the move. The Stochastic labouring in oversold territory is suggestive that short-term traders should not look to bet on a rebound just yet from current levels. Traders hoping for a rebound might prefer to see the price at least starting to trade above the dotted trend line on our chart, accompanied by a sharp move out of oversold territory.

Summary

  • Clover Health is a healthcare technology company providing MA insurance plans to seniors
  • The group also offers a software platform called the Clover Assistant, provide American seniors with highly affordable, ‘obvious’ healthcare plans
  • Clover’s listed debut was through a merger with SPAC Social Capital Hedosophia Holdings Corp III late in 2020
  • The unprecedented gains mid-year can largely be attributed to speculative investments from retail traders coordinated on forums such as Reddit (WallStreetBets)
  • The share price is down more than 50% year to date (as of 21 July 2021)
  • Clover is under investigation by the SEC on allegations that the company and its promoter, Chamath Palihapitiya, misled investors
  • The share price has been in a sharp downtrend since June 2021
Link to comment

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • General Statistics

    • Total Topics
      15,677
    • Total Posts
      74,999
    • Total Members
      63,049
    • Most Online
      7,522
      10/06/21 10:53

    Newest Member
    Scorpiosyd
    Joined 27/07/21 15:11
  • Posts

    • GlaxoSmithKline Q2 revenue is expected to show revenue growth from newer drugs partially offset by increased generic competition in older drugs. Source: Bloomberg   Shares GlaxoSmithKline Price Revenue Vaccine Earnings before interest, taxes, depreciation and amortization  Shaun Murison | Senior Market Analyst, Johannesburg | Publication date: Tuesday 27 July 2021  When is GlaxoSmithKline earnings date? The GlaxoSmithKline (GSK) earnings release date is scheduled for the 28 July 2021. The scheduled results will cover the groups second quarter and half-year earnings.   GSK results preview: What does the street expect? While GlaxoSmithKline (in partnership with Sanofi Pasteur) look to stage three trials of their Covid-19 vaccine, the company has not yet released a vaccine to market. The global rollout of Covid-19 vaccines (by competitors) looks to have disrupted the course of other vaccine programmes in key markets such as the US and the UK for GSK. Revenue for second quarter (Q2) 2021 is expected to be bolstered by sales of newer drugs in the respiratory and HIV segments, with a partial offset from older drugs which are finding increased competition through generic offerings. In terms of the upcoming results, a mean of analyst estimates compiled by Refinitiv data arrive at the following: Revenue $10.433 billion (+10.27%) year on year (YoY) Earnings before interest tax depreciation amortisation (EBITDA) $2.855 billion (-8.91% YoY) Earnings per share (EPS) $0.51 (+10.87% YoY) How to trade the GlaxoSmithKline results   Source: Refinitiv   A Refinitiv poll of analyst ratings arrive have a long term consensus rating of ‘buy’ for GlaxoSmithKline with a target price $47.87. GlaxoSmithKline (ADR) share price: technical analysis   Source: IG The share price of GlaxoSmithKline continues to trade in an uptrend which has been in place since the beginning of March 2021. The price has however started to correct from near term highs. The correction sees the price now testing support at the 38.85 level. Traders looking for long entry might prefer to see a bullish price reversal around current levels accompanied by a sharper move out of oversold territory by the Stochastic oscillator. In this scenario, the recent high at 40.55 would become the initial resistance target, while a close below 38.35 could be used as a stop loss consideration for the trade. However should a bullish price reversal not manifest and we see the price move to close below both the 38.85 and 38.35 support levels, this could instead be a suggestion that the uptrend has failed and perhaps a new downtrend for the share price is forming. In Summary GSK reports Q2 2021 results on the 28 July Q2 revenue of $10.433 billion (+10.27% YoY) is expected Q2 EBITDA of $2.855 billion (-8.91% YoY) are expected EPS $0.51 (+10.87% YoY) in the Q2 are expected The average long term broker rating for GSK is a ‘buy’ The share price of GSK is testing support as it finds itself in a short-term correction of a longer-term uptrend
    • Alibaba continues to enjoy strong revenue and customer growth, but the decline in its stock price reflects a bleaker outlook thanks to the actions of the Chinese government. Source: Bloomberg   Shares Alibaba Group China Investor IPO Price  Chris Beauchamp | Chief Market Analyst, London | Publication date: Tuesday 27 July 2021    When is Alibaba’s earnings date? Alibaba reports earnings on 3 August, covering its fiscal first quarter (Q1). Alibaba earnings – what to expect Alibaba is expected to report revenue of $32 billion, with earnings per share of $2.24. Alibaba continues to enjoy excellent growth, achieving one billion customers in the 2021 financial year (FY2021), with the vast majority of these based in China. Profit margins and revenues have risen at a steady pace in every year since 2013, at 10% and 23% respectively. However, for Chinese tech shares such as Alibaba, the main concern is no longer business performance, but the attitude of the Chinese government instead. The cancellation of the Ant Financial initial public offering (IPO) and the current clampdown on tutoring stocks points towards a much more restrictive approach to the private sector. As many could have predicted, the culture clash between free market capitalism and the controlling instincts of the Chinese Communist Party has begun anew, with the Party determined to rein in the perceived excesses of the free market. This is a situation unfamiliar to many investors, unused to the impact of government interference on most companies except in relatively isolated circumstances, and accounts for the underperformance of Chinese shares, with Alibaba no exception. Find out more on how to buy, sell, and short Alibaba shares Alibaba broker ratings A total of 17 analysts currently rate Alibaba as a ‘strong buy’, with 30 more at ‘buy’. Three analysts have a ‘hold’ rating, and only one ‘sell’. Alibaba stock – technical analysis The direction in Alibaba stock is clear for the time being. Rallies have been regularly sold, with the latest bounce in late June running into the 100-day simple moving average (SMA), currently 22,225. With the macro outlook so unfavourable the stock continues to reflect investor caution, so it looks like further declines are on the cards as the price targets 18,000 and lower.   Source: ProRealTime A solid business, but outlook continues to darken Alibaba has plenty to commend it from a fundamental perspective, but with Beijing adopting an activist position the stock continues to decline. Investors might argue that this means Alibaba is becoming a bargain, but traders will want to see a turnaround in the price, which is unlikely to happen unless the Chinese government reduces its interventions.
    • EUR/USD, GBP/USD and NZD/USD weaken from Fibonacci resistance EUR/USD, GBP/USD and NZD/USD turn lower after posting a deep 76.4% Fibonacci retracement.   Forex NZD/USD EUR/USD GBP/USD Pound sterling Euro    Joshua Mahony | Senior Market Analyst, London | Publication date: Tuesday 27 July 2021  EUR/USD turning lower from latest retracement EUR/USD has managed to post yet another 76.4% Fibonacci retracement, with the pair heading lower once again. This highlights how the trend seen over the course of the past two months remains worth following. While the trend is very shallow in nature, that does bring a higher likeliness of a deep retracement. As such, a bearish outlook holds from here, with a push up through the prior swing-high of $1.183 required to negate that downside bias. Source: ProRealTime GBP/USD turning lower after 76.4% retracement GBP/USD has started to lose ground in early trade today, following the rally into the 76.4% Fibonacci resistance level at $1.383. With a wider bearish trend playing out over recent months, there is a good chance we see further downside from here. A rise up through the $1.391 level would be required to negate that outlook. Source: ProRealTime NZD/USD slumps after deep pullback NZD/USD has similarly turned lower after a 76.4% Fibonacci retracement yesterday. The wider downtrend points towards such a move coming into play, with a rise through $0.7045 required to negate that bearish outlook. Until then, further weakness looks likely from here. Source: ProRealTime
×
×
  • Create New...